Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Cabozantinib for Thyroid Cancer
Recruiting3 awardsPhase 2
Philadelphia, Pennsylvania
This trial is testing whether a drug called cabozantinib is effective at treating patients with a type of thyroid cancer called differentiated thyroid cancer. The trial is open-label, which means that both the patients and doctors will know which patients are taking the drug. The trial is not randomized, which means that the patients will not be assigned to either a treatment group or a control group by chance. The starting dose of cabozantinib is 60mg taken orally once a day. The patients will be able to continue taking the drug as long as it is effective or until they experience side effects that are not tolerable.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.